<DOC>
	<DOCNO>NCT02045940</DOCNO>
	<brief_summary>This study first administration GSK2881078 human . The intention study provide sufficient confidence safety molecule inform progression repeat dose proof concept study . This study include approximately 52 subject consist 2 part . Part A consist two cohort 8 subject assess safety , tolerability , pharmacokinetic ( PK ) ascend single oral dos GSK2881078 . Cohorts 1 2 include healthy male subject . Part B ( Cohorts 3 , 4 5 ) include three cohort 12 healthy male subject examine safety , tolerability , PK , pharmacodynamic ( PD ) repeat dos GSK2881078 14 day . The total duration study include screen follow-up , expect exceed 70 day .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Study GSK2881078 Single Repeat Doses</brief_title>
	<detailed_description />
	<mesh_term>Cachexia</mesh_term>
	<criteria>Males 18 50 year age ( inclusive ) , time signing informed consent form Body weight &gt; = 50 kilogram ( kg ) Body Mass Index ( BMI ) within range 19 32 kg/meter square ( m^2 ) ( inclusive ) , BMI= weight kg/ height m^2 Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male subject female partner childbearing potential must agree use one contraception method list Lifestyle Section protocol . This criterion must follow completion followup visit . Average QTcF &lt; 450millisecond ( msec ) ; QTcF &lt; 480msec subject Bundle Branch Block . Capable give write informed consent , include compliance requirement restriction list consent form . Subjects history clinically significant endocrine , gastrointestinal , hepatic , cardiovascular , neurological , haematological , immunological , renal , respiratory , genitourinary abnormality disease . Subjects history time past coronary artery disease , congestive heart failure , angina , myocardial infarction , cardiac surgery , valvular heart disease , clinically significant arrhythmia , dyspnea , pulmonary edema , stroke , transient ischemic attack . ECG exclusion criterion : Heart rate &lt; 40 &gt; 100 beat per minute , PR Interval &lt; 120 &gt; 200msec , QRS duration &lt; 70 &gt; 110msec . Subjects history malignancy complete remission least 5 year 1 year nonmelanoma skin carcinoma Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History drug alcohol abuse within 5 year prior Screening Period . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 milliliter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Subjects family history early onset prostate cancer multiple member prostate cancer . A positive prestudy drug alcohol screen . Cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Subjects value outside specify range follow Key Clinical Laboratory Tests must exclude study : Liver function test Alanine aminotransferase , Direct Bilirubin , Albumin 10 % outside normal reference range ( &lt; 0.9 x low limit normal [ LLN ] &gt; 1.1 x upper limit normal [ ULN ] ) Renal function Creatinine &gt; 1.6milligrams ( mg ) /deciliter ( dL ) age appropriate glomerular filtration rate &lt; =60 ( mL/minute/1.73 m^2 ) . Electrolytes Sodium Â± 5milliequivalents/Liter outside normal reference range , Potassium Calcium 10 % outside normal reference range ( &lt; 0.9 x LLN &gt; 1.1 x ULN ) Metabolic Glucose 10 % outside normal reference range ( &lt; 0.9 x LLN &gt; 1.1 x ULN ) Total Cholesterol &gt; 240mg/dL Muscle creatine phosphokinase &gt; 2.0 x ULN Hematology Hemoglobin , white blood cell , Neutrophils , Platelets 10 % outside normal reference range ( &lt; 0.9 x LLN &gt; 1.1 x ULN ) Prostate Specific Antigen &gt; 2.5nanogram/mL A positive test human immuno virus antibody A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Exposure four new chemical entity within 12 month prior first dose day Unable refrain prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication throughout study , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 3 month ( 12 week ) , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Where participation study would result donation blood blood product excess 500mL within 56day period . Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>FTIH</keyword>
	<keyword>safety</keyword>
	<keyword>SARM</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>